AAPL 258.2 1.1478% MSFT 439.33 0.9374% NVDA 140.22 0.3938% GOOGL 196.11 0.7604% GOOG 197.57 0.8062% AMZN 229.05 1.7729% META 607.75 1.317% AVGO 239.68 3.1547% TSLA 462.28 7.3572% TSM 206.33 -0.4967% LLY 795.67 -0.0766% V 320.65 1.0813% JPM 242.31 1.6444% UNH 506.1 -0.0474% NVO 87.37 -1.5105% WMT 92.68 2.5789% LVMUY 132.15 0.1516% XOM 106.4 0.0941% LVMHF 655.0 -0.2543% MA 535.71 1.2761%

Cardio Diagnostics Holdings Inc

Healthcare US CDIO

1.01USD
-0.02(1.94%)

Last update at 2024-12-24T21:57:00Z

Day Range

0.951.05
LowHigh

52 Week Range

0.173.56
LowHigh

Fundamentals

  • Previous Close 1.03
  • Market Cap15.88M
  • Volume1345441
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.13084M
  • Revenue TTM0.02M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 0.00090M
  • Diluted EPS TTM-0.77

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -4.66099M -0.62045M -0.60516M
Minority interest - - -
Net income -4.66099M -0.62045M -0.60516M
Selling general administrative 4.40M 0.47M 0.59M
Selling and marketing expenses 0.09M 0.10M 0.00548M
Gross profit 0.00095M 0.00090M -
Reconciled depreciation 0.02M 0.02M 0.01M
Ebit -4.43592M -0.62045M -0.60916M
Ebitda -4.41992M -0.60445M -0.59850M
Depreciation and amortization 0.02M 0.02M 0.01M
Non operating income net other - - -
Operating income -4.54845M -0.62045M -0.60916M
Other operating expenses 4.55M 0.62M 0.61M
Interest expense - - -
Tax provision 0.00000M 0.00000M 0.00000M
Interest income - - -
Net interest income - - -
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense 0.11M - -
Total revenue 0.00095M 0.00090M 0.00000M
Total operating expenses 4.55M 0.62M 0.61M
Cost of revenue - - -
Total other income expense net -0.11253M - 0.00400M
Discontinued operations - - -
Net income from continuing ops -4.66099M -0.62045M -0.60516M
Net income applicable to common shares - -0.62045M -0.60516M
Preferred stock and other adjustments - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 4.46M 6.25M 1.10M 0.45M
Intangible assets 0.54M 0.36M 0.30M 0.20M
Earning assets - - - -
Other current assets 1.22M 1.77M 0.04M 0.00883M
Total liab 1.50M 1.95M 0.03M 0.39M
Total stockholder equity 2.96M 4.30M 1.07M 0.06M
Deferred long term liab - - - -
Other current liab 0.22M - - 0.39M
Common stock 0.00020M 0.00010M 0.00123M 0.00105M
Capital stock 0.00020M 0.00010M 0.00123M 0.00105M
Retained earnings -14.36838M -5.99155M -1.33056M -0.71011M
Other liab - - - -
Good will - - - -
Other assets - - - -
Cash 1.28M 4.12M 0.51M 0.24M
Cash and equivalents - - - -
Total current liabilities 0.84M 0.85M 0.03M 0.39M
Current deferred revenue -0.22393M - - -
Net debt -0.02250M -4.11752M -0.51277M -0.23709M
Short term debt 0.60M - - -
Short long term debt - - - -
Short long term debt total 1.26M - - -
Other stockholder equity 17.33M 10.29M 2.40M 0.77M
Property plant equipment - - - -
Total current assets 2.77M 5.89M 0.80M 0.25M
Long term investments - - - -
Net tangible assets - - 0.77M -0.14009M
Short term investments - - - -
Net receivables 0.26M 0.00000M 0.00090M 0.00000M
Long term debt - - - -
Inventory - - 0.25M -
Accounts payable 0.24M 1.10M 0.03M 0.04M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income 0.00000M - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.01M 0.00495M - -
Deferred long term asset charges - - - -
Non current assets total 1.70M 0.36M 0.30M 0.20M
Capital lease obligations 0.89M - - -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -0.36800M -0.36403M -0.02991M
Change to liabilities - -0.00565M 0.04M
Total cashflows from investing activities - -0.36403M -0.02991M
Net borrowings - - -
Total cash from financing activities 9.06M 1.23M 0.24M
Change to operating activities - -0.03101M -0.00807M
Net income -4.66099M -0.62045M -0.60516M
Change in cash 3.60M 0.28M 0.24M
Begin period cash flow 0.51M 0.24M 0.00114M
End period cash flow 4.12M 0.51M 0.24M
Total cash from operating activities -5.09097M -0.58529M 0.03M
Issuance of capital stock 11.99M 1.12M 0.00000M
Depreciation 0.02M 0.02M 0.01M
Other cashflows from investing activities - -0.25000M -0.25000M
Dividends paid - - -
Change to inventory - - -
Change to account receivables 0.00090M -0.00090M -0.00090M
Sale purchase of stock - - -
Other cashflows from financing activities -2.92231M 0.10M 0.24M
Change to netincome - 0.06M 0.59M
Capital expenditures 0.08M 0.11M 0.03M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital -0.55852M -0.03756M 0.03M
Stock based compensation 0.00000M 0.06M 0.59M
Other non cash items 0.11M -0.00328M -
Free cash flow -5.16712M -0.69932M -0.00405M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CDIO
Cardio Diagnostics Holdings Inc
-0.02 1.94% 1.01 - - 1404.40 8.10 1381.17 -15.403
NVO
Novo Nordisk A/S
-1.34 1.51% 87.37 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
0.75 0.86% 87.75 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
2.91 0.72% 408.18 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
-0.66 0.09% 714.47 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Cardio Diagnostics Holdings Inc

400 North Abderdeen Street, Chicago, IL, United States, 60642

Key Executives

Name Title Year Born
Dr. Meeshanthini Dogan Ph.D. Co-Founder, CEO & Director 1989
Dr. Robert A. Philibert M.D., Ph.D. Co-Founder, Chief Medical Officer & Director 1962
Ms. Elisa Michael Luqman J.D., M.B.A. CFO & Director 1964
Mr. Timur Dogan Ph.D. Chief Technology Officer 1988
Ms. Khullani Abdullah J.D. VP of Revenue & Strategy 1983
Dr. Meeshanthini V. Dogan Ph.D. Co-Founder, CEO & Director 1989
Ms. Elisa Michael Luqman Esq., J.D., M.B.A. Chief Financial Officer 1964
Ms. Khullani Abdullahi J.D. Vice President of Revenue & Strategy 1984

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.